Basic Information
| LncRNA/CircRNA Name | MIAT |
| Synonyms | myocardial infarction-associated transcript |
| Region | GRCh38_22:26646428-26676475 |
| Ensemble | ENSG00000225783 |
| Refseq | NR_003491 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | RT-qPCR, RNAi, Dual luciferase reporter assay, Western blot analysis |
| Sample | NSCLC tissues,NSCLC H1299 and CDDP resistant H1299 (H1299-CDDP) cells |
| Expression Pattern | up-regulated |
| Function Description | MIAT expression was significantly upregulated in NSCLC tissues, particularly in aggressive cases, and was highly associated with a poor prognosis. In addition, the upregulated expression of MIAT was observed in cisplatin (CDDP)-resistant H1299 cells. Knockdown of MIAT inhibited the proliferation of NSCLC cells and enhanced the sensitivity of NSCLC cells to CDDP in vitro and in vivo. Further functional analysis demonstrated that MIAT partially exerted its oncogenic effect by upregulating the expression of splicing factor 1 (SF1), by serving as a microRNA (miR)-184 sponge. |
| Pubmed ID | 31897168 |
| Year | 2020 |
| Title | Knockdown of lncRNA MIAT Inhibits Proliferation and Cisplatin Resistance in Non-Small Cell Lung Cancer Cells by Increasing miR-184 Expression |
External Links
| Links for MIAT | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |